Genomma Lab Delivers Remarkable Top Line Growth of 122.4% and EBITDA Growth of 139.3% in 4Q09

GENOMMA LAB INTERNACIONAL ANNOUNCES FOURTH QUARTER AND FULL YEAR 2009 RESULTS

Mexico City, Mexico – February 24, 2010

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the fourth quarter and full year periods ended December 31, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

4Q09 Highlights (vs. 4Q08)

- Net Sales for the quarter reached Ps. 1,666.4 million, an increase of 122.4%.
- EBITDA[1] increased 139.3%, to Ps. 507.6 million. This represents a 30.5% margin during the fourth quarter.
- Earnings per Share[2] increased 49.0%, to Ps. 1.44.
- International Net Sales rose 84.7%, to Ps. 190.8 million.
- During the fourth quarter, Genomma Lab successfully launched 11 products under 6 existing brands (Base Brands[3] and Prior Year Launches[4]) as part of its line extension strategy.

[1] EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.
[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.
[3] As defined below.
[4] As defined below.

Investor Relations Contact: Oscar Villalobos
Tel: +52 (55) 5081 0000 Ext. 4250
E-mail: inversion@genommalab.com

In New York: i-advize Corporate Communications, Inc.
Tel: (212) 406-3692
E-mail: genomma@i-advize.com

Full Year 09 Highlights (vs. 08)

- Net Sales reached Ps. 4,424.7 million, an increase of 68.3%.
- EBITDA[5] increased 65.5%, to Ps. 1,143.6 million. This represents a 25.8% margin during the period.
- Earnings per Share[6] increased 34.6% to Ps. 1.44 during 2009.
- International Net Sales rose 183.0%, to Ps. 618.4 million.
- Consolidated Net Income increased 48.2% to Ps. 760.0 million.
- During 2009, Genomma Lab successfully launched 25 products under 15 existing brands (Base Brands[7] and Prior Year Launches[8]) as part of its line extension strategy.
- The Company also launched 216 products under 13 New Brands[9], as part of its new product launch plan during the year.

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, stated: "We are excited to report Genomma Lab's fourth quarter 2009 results, which once again show remarkable growth as well as profitability. During this period we saw that the public demand for our products not only remained strong, but increased significantly. Fourth quarter 2009 sales are solid proof that the Company's business model and advertising strategies continue to be successful. We are very pleased to have ended such an economically challenging year in a positive manner, increasing our sales and profitability and increasing, as a result, our shareholder value.

We are especially optimistic about Genomma Lab's entrance into the North American and Brazilian markets. Through these new ventures we continue to expand our international presence; as we have mentioned before, these two markets represent an important opportunity for the Company. We are confident that our business model will be as successful in these countries as it has been in Mexico and other countries in Latin America.

Despite the outstanding results obtained during the fourth quarter of 2009, we reiterate our issued guidance with a Net Sales growth between 42% and 45% and an EBITDA margin between 25% and 26% for 2010.

[5] EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.

[6] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.

[7] As defined below.

[8] As defined below.

[9] As defined below.

In conclusion, it is important to recognize the challenging economic environment we are emerging from. However, we are proud to see that not only has the Company overcome this situation, but has also grown significantly throughout its duration. We will remain cautious until the effects of these economic conditions have ended while we continue to develop and launch innovative products under premium brands, aiming to drive growth in revenues, earnings and cash generation.

Consolidated Results of Operations for the Fourth Quarter and Full Year 2009

The following table shows our condensed and consolidated results of operations, in millions of pesos (except share and per-share data), the margin for each concept, as a percentage of Net Sales, as well as the variation in terms of percentage for the quarter and full year periods ended December 31, 2009 compared to the same period in 2008:

For the quarter and full year periods ended December 31, 2009 and 2008
(In millions of current Mexican pesos)

	4rd Quarter			Jan - Dec		
	2009	2008	%Var	2009	2008	%Var
Net Sales	1,666.4	749.2	122.4	4,424.7	2,629.4	68.3
Gross Profit	1,201.4	545.5	120.2	3,187.1	1,967.2	62.0
Gross Margin	72.1%	72.8%	(0.7)	72.0%	74.8%	(2.8)
EBITDA[1]	507.6	212.1	139.3	1,143.6	691.1	65.5
EBITDA Margin[1]	30.5%	28.3%	2.1	25.8%	26.3%	(0.4)
Operating Income	487.9	206.2	136.7	1,090.7	672.7	62.1
Consolidated Net Income	376.1	192.7	95.1	760.0	512.8	48.2
Consolidated Net Income Margin	22.6%	25.7%	(3.1)	17.2%	19.5%	(2.3)
Weighted average number of shares outstanding	526,539,365	529,240,713	(0.5)	527,303,567	478,922,792	10.1
EPS (12 meses)[2]	1.44	0.97	49.0	1.44	1.07	34.6

[1]EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income. Out of the Ps. 26.6 million that were considered as pre operative expenses only 6.3 million were capitalized on 4Q09 according to International Financial Rules and Mexican GAAP

[2]Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of December 31, 2009 totaled 526,474,713.

Net Sales rose 122.4% to Ps. 1,666.4 million in the fourth quarter of 2009, from Ps. 749.2 million in the fourth quarter of 2008. This increase resulted from the combination of the following: i) an 83.1% increase (Ps. 504.1 million) from **Base Brands** in Mexico, to Ps. 1,110.8 million, including line extensions on these brands; ii) a 98.6% increase (Ps. 38.6 million) due to the full year effect of **Prior Year Launches** in Mexico, including recent line extensions on these brands launched during 2008 to reach Ps. 77.8 million; iii) Ps. 286.9 million in the fourth quarter of 2009 from **New Brands** in Mexico due to the launch of 216 new products under 13 New Brands during the year; and iv) an 84.7% increase (Ps. 87.5 million) in **International** operations to Ps. 190.8 million.

We classify Net Sales by brands in the following manner:

1) **Base Brands** were launched at least two years prior to the last fiscal year (2007, 2006, 2005, etc),
2) **Prior Year Launches** were brands launched during the prior fiscal year (2008),
3) **New Brands** were launched in the current fiscal year (2009), and
4) **International** refers to Net Sales from our international operations.

Net Sales for the Full Year rose 68.3% to Ps. 4,424.7 million for 2009 from Ps. 2,629.4 million for 2008. This increase resulted from the combination of the following: i) 19.8% (Ps. 454.2 million) from **Base Brands** in Mexico to Ps. 2,750.7 million, including line extensions on these brands, ii) 109.7% (Ps. 125.5 million) due to the full year effect of **Prior Year Launches** in Mexico, including recent line extensions on these brands launches during 2008, to reach Ps. 239.9 million, iii) Ps. 815.6 million in 2009 from **New Brands** in Mexico due to the launch of 216 new products under 13 New Brands throughout the year, and iv) a 183.0% increase (Ps. 399.9 million) in our **International** operations to Ps. 618.4 million.

The following tables show Net Sales for 2009 and 2008 detailed by brand:

(In millions of Pesos)

BRAND	NET SALES 2009	% OF TOTAL NET SALES 2009	NET SALES 2008	% OF TOTAL NET SALES 2008	VAR % 2009 VS 2008
ASEPXIA	378.1	8.5%	252.6	9.6%	49.7%
PRIMER NIVEL	344.0	7.8%	0.0	0.0%	NA
LINEA M	259.7	5.9%	289.4	11.0%	-10.3%
CICATRICURE	241.6	5.5%	241.2	9.2%	0.2%
NIKZON	225.4	5.1%	172.8	6.6%	30.4%
GOICOECHEA	186.6	4.2%	158.3	6.0%	17.9%
METABOL TONICS	176.6	4.0%	80.3	3.1%	119.9%
MA EVANS	166.4	3.8%	40.1	1.5%	315.2%
BENGUE	146.7	3.3%	114.2	4.3%	28.5%
GENOPRAZOL	142.8	3.2%	138.1	5.3%	3.4%
SILKA MEDIC	131.6	3.0%	108.4	4.1%	21.5%
QG5	125.3	2.8%	0.0	0.0%	NA
DALAY	125.2	2.8%	82.1	3.1%	52.5%
X RAY	124.1	2.8%	170.2	6.5%	-27.1%
SUBTOTAL	2774.1	62.7%	1847.7	70.3%	50.1%
OTHER BRANDS (<2.5%)	1032.2	23.3%	563.2	21.4%	83.3%
TOTAL NATIONAL	3806.3	86.0%	2410.9	91.7%	57.9%
INTERNATIONAL	618.4	14.0%	218.5	8.3%	183.0%
TOTAL	4424.7	100.0%	2629.4	100.0%	68.3%

Gross Profit increased 120.2% to Ps. 1,201.4 million in the fourth quarter 2009 compared to Ps. 545.5 million during the fourth quarter of 2008. Gross Margin decreased 0.7 percentage points, as a percentage of Net Sales, to 72.1% in the fourth quarter of 2009, compared to 72.8% for the same period of 2008. This decrease was primarily attributable to a higher cost of goods sold as a percentage of Net Sales in our *Primer Nivel Por Tu Salud* product portfolio. This was partially offset by a change in the sales mix, with an increasing presence in our OTC products which have a lower cost of goods sold as a percentage of Net Sales.

Gross Profit for the Full Year increased by 62.0% to Ps. 3,187.1 million for 2009 compared to Ps. 1,967.2 million for 2008.

Selling, General and Administrative Expenses, as a percentage of Net Sales, decreased 2.5 percentage points to 42.8% in the fourth quarter of 2009 from 45.3% in the fourth quarter of 2008. This decrease was mainly due to economies of scale achieved by the strong increase in sales during the period. This decline was partially offset by higher advertising as a percentage of Net Sales mainly in our *Primer Nivel por tu Salud* product portfolio as well as in other new product launches.

Selling, General and Administrative Expenses for the Full Year, as a percentage of net sales, decreased 1.9 percentage points to 47.3% for 2009 from 49.2% for 2008.

EBITDA increased 139.3% to Ps. 507.6 million in the fourth quarter of 2009, compared to Ps. 212.1 million in the fourth quarter of 2008. The EBITDA margin increased 2.1 percentage points as a percentage of Net Sales to 30.5% for the fourth quarter of 2009 from 28.3% for the fourth quarter of 2008. The EBITDA margin increase was primarily due to a decline in the Selling, General and Administrative Expenses as a percentage of Net Sales, which was partially offset by a higher cost of goods sold as a percentage of Net Sales, for the aforementioned reasons.

EBITDA for the Full Year increased 65.5% to Ps. 1,143.6 million for 2009 compared to Ps. 691.1 million for 2008.

EBITDA Reconciliation

For the fourth quarter and full year period ended on December 31, 2009 and 2008
(In millions of current Mexican pesos)

	4Q		Full Year	
	2009	**2008**	**2009**	**2008**
Consolidated net income (loss)	376.1	192.7	760.0	512.8
Discontinued operations	12.3	12.2	11.5	26.0
Income tax expense (benefit)	86.2	57.4	305.3	194.2
Comprehensive financing (income) cost	14.2	(50.6)	13.3	(61.9)
Other expense, Net	(1.3)	(5.6)	0.1	1.5
Non consolidated monetary position	0.4	-	0.4	-
Income from Operations	487.9	206.2	1,090.7	672.7
+Pre-operating expenses	14.2	-	20.3	-
+Depreciation and Amortization	5.4	6.0	32.6	18.4
EBITDA	507.6	212.1	1,143.6	691.1
EBITDA Margin	30.5%	28.3%	25.8%	26.3%

Operating Income increased 136.7% to Ps. 487.9 million in the fourth quarter of 2009 compared to Ps. 206.2 million in the fourth quarter of 2008. Operating margin increased 1.8 percentage points, as a percentage of Net Sales, to 29.3%, compared to 27.5% for same period in 2008. This increase was primarily due to the aforementioned decreases in Selling, General and Administrative expenses as a percentage of Net Sales, in addition to a decrease in Amortization due to the reclassification of pre-operating expenses from Colombia which were initially capitalized and amortized accordingly.

Operating Income for the Full Year increased 62.1% to Ps. 1,090.7 million for 2009 compared to 672.7 million for 2008.

Comprehensive Financing Cost was Ps. 14.2 million for the fourth quarter of 2009, which represented an increase of Ps. 64.8 million compared to the Ps. 50.6 million financing income reported for the fourth quarter of 2008. The increase was primarily a result of: i) lower interest income, to Ps. 3.9 million for the fourth quarter of 2009 from Ps. 18.1 million in the same period of 2008, primarily due to higher average cash balances in 2008 and a decrease in interest rate received from bank accounts in pesos as well as in dollars, ii) an increase in the monetary position gain to Ps. 3.1 million in the fourth quarter of 2009, compared to a Ps. 1.5 million loss for the fourth quarter of 2008; iii) a foreign exchange loss of Ps. 16.1 million in the fourth quarter of 2009, from a Ps. 41.0 million gain during the same period of 2008, primarily due to the depreciation of U.S. dollar balances versus the Mexican peso for the period; iv) an increase in financial expenses of Ps. 0.1 million to Ps. 6.1 million during the fourth quarter of 2009 from Ps. 6.0 million during the same period of 2008; and v) an increase of Ps. 2.2 million from the effects of the exchange rate in foreign operations, to a Ps. 1.1 million gain in the fourth quarter of 2009 from a loss of Ps. 1.1 million during the same period of 2008, due to the appreciation of the currencies in our operations during the corresponding periods. As of December 31, 2009, the Company maintained a U.S. dollar cash position of US$ 20.5 million.

Comprehensive Financing Cost for the Full Year represented Ps. 13.3 million in 2009, which was an increase of Ps. 75.2 million compared to the gain of Ps. 61.9 million reported for the same period in 2008.

As of December 31, 2009, Genomma Lab had a total cash position, held in dollars and pesos, of Ps. 1,059.4 million.

Consolidated Net Income increased 95.1% to Ps. 376.1 million in the fourth quarter of 2009 compared to Ps. 192.7 million in the fourth quarter of 2008. Consolidated Net Income, as a percentage of sales, decreased 3.1 percentage points to 22.6% in the fourth quarter of 2009 compared to 25.7% in the same period of 2008.

Consolidated Net Income for the Full Year increased 48.2% to Ps. 760.0 million for 2009 from Ps. 512.8 million reported for 2008. Consolidated Net Income, as a percentage of net sales, decreased 2.3 percentage points to 17.2% for 2009 from 19.5% for 2008.

Balance Sheet

As of December 31, 2009, September 30, 2009 and December 31, 2008
(In millions of current Mexican pesos for the amounts of December 2009, September 2009 and December 2008)

	December 31, 2009	December 31, 2008	% Var Dec 09 vs Dec 08	Var Dec 09 vs Dec 08	September 30, 2009	% Var Dec 09 vs Sep 09	Var Dec 09 vs Sep 09
Balance Sheet Information:							
Cash and equivalents	1,059.4	1,291.0	-17.9%	(231.7)	1,019.2	3.9%	40.2
Trade receivables	1,336.9	688.9	94.1%	648.0	1,080.7	23.7%	256.2
Inventories	630.1	407.7	54.6%	222.4	647.0	-2.6%	(16.8)
Other current assets	340.6	206.6	64.8%	133.9	298.7	14.0%	41.9
Total Assets	4,241.7	2,839.9	49.4%	1,401.7	3,755.9	12.9%	485.7
Suppliers	594.3	377.2	57.6%	217.1	564.6	5.3%	29.7
Other current liabilities	473.0	134.1	252.6%	338.9	341.2	38.6%	131.8
Loans with financial institutions	-	-		-	-		-
Total Liabilities	1,190.9	527.8	125.6%	663.1	1,080.9	10.2%	110.0
Stockholders Equity	3,050.7	2,312.1	31.9%	738.6	2,675.0	14.0%	375.7
Working Capital (1)	2,299.7	2,083.0	10.4%	216.7	2,139.7	7.5%	160.0
Working Capital less cash	1,240.3	792.0	56.6%	448.3	1,120.5	10.7%	119.8
Trade Recevables days	109	94	15.3%	15	111	-1.9%	(2)
Inventories days	183	222	-17.3%	(39)	239	-23.2%	(56)
Suppliers days	173	205	-15.7%	(32)	208	-17.0%	(35)
Cash Conversion Cycle	119	111	7.5%	8	141	-15.6%	(22)

(1) Working capital consists of current assets minus current liabilities.

Cash and Equivalents decreased 17.9% (Ps. 231.7 million) to Ps. 1,059.4 million on December 31 2009, compared to Ps. 1,291.0 million on December 31, 2008. This decrease was mainly due to cash consumption related to: I) working capital in the amount of Ps. 765.7 million; ii) acquisitions during 2009 for a total of Ps. 466.0 million, of which Ps. 303.3 million have been paid; iii) the transfer of funds to the stock repurchase program in the amount of Ps. 20.0 million; iv) funding for the Employee Compensation Program in the amount of Ps. 40.0 million and v) Ps. 178.3 million of capital expenses mainly allocated for the recording studios. This consumption was partially offset by the Company's cash generation of the last twelve months.

Trade Receivables increased 94.1% (Ps. 648.0 million) to Ps. 1,336.9 million on December 31, 2009 from Ps. 688.9 million on December 31, 2008. Days of Trade Receivables increased 15 days, to 109 days on December 31, 2009 from 94 days on December 31, 2008. This increase came as a result of the Company`s substantial growth during the period. The collection cycle during the period is in line with the terms agreed with our clients.

Inventories increased 54.6% (Ps. 222.4 million) to Ps. 630.1 million on December 31, 2009 from Ps. 407.7 million on December 31, 2008. Days of Inventories decreased 39 days, to 183 days on December 31, 2009 from 222 days on December 31, 2008. This decrease was mainly attributable to higher than expected sales during the period, and was partially offset by an inventory buildup for the Brazilian and US operations.

Suppliers increased 57.6% (Ps. 217.1 million) to Ps. 594.3 million on December 31, 2009, from Ps. 377.2 million on December 31, 2008. Days of Suppliers decreased 32 days, to 173 days on December 31, 2009 from 205 days on December 31, 2008. This change was mainly due to the Company standardizing relations with its suppliers.

Cash Conversion Cycle reached 119 days, which is in line with the Company`s corporate target of 120 days.

Other Current Assets increased 64.8% (Ps. 133.9 million) to Ps. 340.6 million on December 31, 2009 from Ps. 206.6 million on December 31, 2008. This increase was mainly attributable to: i) an increase in receivable taxes due to pending VAT tax refunds; and ii) prepaid advertising.

Other Current Liabilities increased 252.6% (Ps. 338.9 million) to Ps. 473.0 million on December 31, 2009 from Ps. 134.1 million on December 31, 2008. This increase was attributable mainly to an increase in income taxes payable combined with an increase in other creditors due to higher standard operating expenses.

During the fourth quarter of 2009, cash flow from operations and cash on hand was sufficient to meet the Company's liquidity requirements.

Operations Summary

Net Sales for the Fourth quarter

For the fourth quarter of 2009, Net Sales of OTC pharmaceutical products increased 149.8%[10] compared to the fourth quarter of 2008. During the fourth quarter of 2009, the Company launched 1 new OTC product.

For the year 2009, sales of OTC pharmaceutical products increased 48.2%[11] compared to 2008.

Net sales of personal care products increased 68.7%[12] for the fourth quarter of 2009 compared to the fourth quarter of 2008. During the fourth quarter of 2009 the Company launched 10 new personal care products.

Sales of personal care products increased 36.4%[13] for 2009, compared to 2008.

During the fourth quarter of 2009 the Company launched 35 new generic pharmaceutical products.

Net sales in international operations increased 84.7% to Ps. 190.8 million for the fourth quarter of 2009 compared to Ps. 103.3 million for the same period in 2008. This increase was due to a strong growth in our Latin American operations, mainly driven by sales from the Argentine and Colombian operations.

Net sales in International operations increased 183.0% for the Full Year 2009 to Ps. 618.4 million compared to Ps. 218.5 million for the same period in 2008.

[10] Includes only OTC pharmaceutical products in Mexico.
[11] Includes only OTC pharmaceutical products in Mexico.
[12] Includes only personal care products in Mexico.
[13] Includes only personal care products in Mexico.

New Products Launches and Line Extensions

During 2009, Genomma Lab launched 25 line extensions of **Base Brands** and **Prior Year Launches;** and 216 new products under 13 **New Brands**; among these were:

Bio-Nrgy is a line extension of our analgesics brand *Bio-electro* consisting of OTC tablets that help eliminate headaches and migraines without causing drowsiness or fatigue. Its formula is based on Paracetamol and Caffeine.

Bio-Dual is also a line extension of our analgesics brand *Bio-electro* consisting of OTC tablets that help eliminate headaches and migraines with a sleep aid due to its formula based on Paracetamol and Difenhidramina.

Tío Nacho - Aclarante is a brand purchased in 2008 for its top of mind recognition in the shampoo category. Its chamomile formula restores and lightens hair.

Other Events

- On December 22, 2009, the Company released its 2010 earnings guidance, expecting net sales growth in the range of 42% to 45% for the full year of 2010, excluding possible acquisitions, and an EBITDA margin between 25.0% and 26.0%, from 2009 year-end results.

- During the fourth quarter of 2009 the improvement in the liquidity of the stock was mainly driven by: i) a broader base of investors; ii) a solid financial performance; iii) a continuous growth above expectations; iv) an increase in the free float reaching 32.3% of total shares outstanding; and v) the support of UBS as a market maker to increase de number of transactions and to diminish the buy/sell differential. As a result of the above, the Company`s stock has moved from the 48th position[14] to the 28th position of the Mexican Stock Exchange liquidity index in only 12 months.

- The Company has decided to acquire its own corporate headquarters to fulfill the needs of its employees. The new facilities will include 6,000 m^2 with a transaction cost of US. 11.25 million and will be located in Mexico City in the Santa Fe area.

[14] Excluding Naftrac, Ilctrac and C.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab counts with a combination of a successful new products development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated Income Statements

2009 and 2008
(In thousands of current Mexican pesos)

	4Q			Full Year		
	2009	2008	% Var	2009	2008	% Var
Net sales	1,666,359	749,201	122.4%	4,424,655	2,629,431	68.3%
Costs and expenses:						
Cost of sales	464,973	203,655	128.3%	1,237,519	662,246	86.9%
Selling, general and administrative expenses	713,486	339,384	110.2%	2,096,437	1,294,526	61.9%
Total costs and expenses	1,178,458	543,039	117.0%	3,333,956	1,956,772	70.4%
Income from operations	487,901	206,161	136.7%	1,090,700	672,659	62.1%
Other (expense)- Net	1,291	5,591	-76.9%	(50)	(1,483)	-96.6%
Comprehensive financing income (cost)						
Interest (expense)	(7,394)	(5,977)	23.7%	(14,439)	(21,096)	-31.6%
Interest income	5,136	18,116	-71.6%	38,864	42,878	-9.4%
Exchange gain (loss)	(16,145)	41,006	-139.4%	(39,216)	44,205	-188.7%
Monetary position (loss)	3,098	(1,504)	-305.9%	(965)	(3,311)	-70.9%
Effects of exchange rate changes on foreign operations	1,065	(1,067)	-199.8%	2,430	(791)	-407.1%
Total financing income	(14,241)	50,574	-128.2%	(13,326)	61,886	-121.5%
Non consolidated monetary position	(399)	-		(399)	-	
Income before income taxes	474,552	262,326	80.9%	1,076,924	733,061	46.9%
Income tax expense (benefit)	86,182	57,438	50.0%	305,345	194,209	57.2%
Discontinued operations (loss)	(12,281)	(12,165)	0.9%	(11,543)	(26,018)	-55.6%
Consolidated net income (loss)	376,089	192,723	95.1%	760,036	512,835	48.2%
Consolidated net income (loss)	376,089	192,723	95.1%	760,036	512,835	48.2%
Net loss (income) of minority stockholders	822	1,512	0.0%	(1,297)	2,941	-144.1%
Net income of majority stockholders	376,911	194,235	94.0%	758,739	515,776	47.1%

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated balance sheets
For the periods December, 2009, December, 2008 and September, 2009
(In thousands of current Mexican pesos)

	Dec-09	Dec-08	V$	V%	Sep-09	V$	V%
Assets							
Current assets:							
Cash and equivalents	1,059,380	1,291,048	(231,668)	-17.9%	1,019,198	40,182	3.9%
Share buy back fund	8,142	24,084	(15,942)	-66.2%	16,131	(7,989)	-49.5%
Employee Share buy back fund	10,894	-	10,894	0.0%	15,499	(4,605)	-29.7%
Accounts receivable-Net	1,545,647	755,108	790,539	104.7%	1,283,081	262,566	20.5%
Inventory - Net	630,121	407,710	222,411	54.6%	646,960	(16,839)	-2.6%
Prepaid expenses and other current assets	81,996	104,477	(22,481)	-21.5%	49,335	32,662	66.2%
Due from related parties	30,795	11,887	18,908	159.1%	15,371	15,424	100.3%
Discontinued operations	3,407	22,917	(19,510)	-85.1%	23,191	(19,784)	-85.3%
Total current assets	3,370,383	2,617,231	753,152	28.8%	3,068,766	301,617	9.8%
Equipment- net	260,698	107,715	152,983	142.0%	163,245	97,453	59.7%
Trademarks	446,653	80,626	366,027	454.0%	435,879	10,774	2.5%
Investments in subsidiaries	25,166	-	25,166	0.0%	0.00004	25,166	0.0%
Investments available for sale			-	-	-	-	-
Deferred income tax	2,869	1,108	1,761	158.9%	29,486	(26,617)	-90.3%
Other assets- Net	135,844	32,820	103,024	313.9%	58,138	77,706	133.7%
Discontinued operations	38	424	(386)	-91.0%	432	(394)	-91.2%
	610,570	114,979	495,591	431.0%	523,935	86,635	16.5%
Total Assets	4,241,651	2,839,926	1,401,726	49.4%	3,755,947	485,705	12.9%
Current Liabilities:							
Loans with financial institutions	-	-	-	0.0%	-	-	0.0%
Trade accounts payable	594,279	377,180	217,099	57.6%	564,616	29,663	5.3%
Due to related parties	81	119	(39)	0.0%	35	46	132.2%
Accrued expenses and taxes other than income taxes	389,295	99,350	289,945	291.8%	205,362	183,933	89.6%
Deferred Income	-	-	-	0.0%	-	-	-
Income tax payable	37,640	34,665	2,974	8.6%	135,844	(98,204)	-72.3%
Statutory employee profit sharing	3,382	1,838	1,544	84.0%	5,164	(1,781)	-34.5%
Discontinued operations	4,656	9,871	(5,215)	-52.8%	4,335	321	7.4%
Deferred income tax	46,006	-	46,006	-	-	46,006	0.0%
Employee retirement obligations	7,491	4,765	2,725	57.2%	7,401	90	1.2%
Trade accounts payable LP	108,090	9,871	98,219	995.0%	158,156	(50,066)	-31.7%
Total Liabilities	1,190,920	527,788	663,131	125.6%	1,080,912	110,008	10.2%
Capital stock	274,924	274,924	-	0.0%	274,924	-	-
Additional paid in capital	1,553,938	1,553,938	-	0.0%	1,553,938	-	-
Retained earnings	519,636	(37,296)	556,933	-1493.3%	519,636	-	-
Net income	758,739	515,776	242,963	47.1%	381,428	377,310	98.9%
Cumulative translation effects of foreign subsidiaries	1,228	4,796	(3,569)	-74.4%	2,065	(837)	-40.5%
Share buyback fund	(62,965)	-	(62,965)	0.0%	(65,037)	2,072	-3.2%
Superavit with related parts	(3,721)	-	(3,721)	0.0%	(65,037)	61,317	-94.3%
Minority Interest	8,953		8,953	0.0%	8,081	872	11%
Total stockholders equity	3,050,731	2,312,137	738,594	31.9%	2,675,035	375,697	14.0%

Cash Flow Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated Cash Flow Statements
(In thousands of current Mexican pesos)

	2009 4Q	2009 Full Year
Operating activities:		
Income for continued operations	474,553	1,076,924
Items that did not require resources:		
Depreciation and amortization	5,447	32,605
Not realized foreign exchange gains or losses	904	1,022
Gain on fixed assets sale	189	178
Impairment assets	4,300	4,300
Income tax	(79,116)	31,012
Non consolidating minority position	399	399
Employee termination obligations, net	90	2,726
Employee profit sharing	(3,326)	-
Other financing activites	6,823	11,628
Cash flow from operations	410,262	1,160,794
(Increase) Decrease in accounts receivable	(128,923)	(836,978)
(Increase) Decrease in inventories	17,906	(220,822)
Increase (Decrease) in accounts payable	(44,092)	216,871
Increase (Decrease) in payable tax	22,644	(22,584)
Other, Net	(32,661)	22,481
Shared based payments	15,356	44,633
Discontinued operations	7,823	2,752
Changes in Working Capital		
Net cash flow generated (used) in operating activities	268,315	367,147
Net Cash flow generated (used) in operating activities after discontined operations	268,315	367,147
Investing activities:		
Divestments (investments)	(103,072)	(178,281)
Asset sales (other capital expenditures)	(88,658)	(320,678)
Investment in subsidiaries	(25,565)	(25,565)
Discontinued operations	394	387
Net cash flow generated (used) in investing activities	(216,901)	(524,137)
	-	
Net cash flow from Investing	51,414	(156,990)
Financing activities:		
Stock repurchases	(17,003)	(69,941)
Payable interest from prior periods	(6,823)	(11,628)
Gain on stock repurchases	-	(221)
Minority interest	2,093	6,880
Net cash flow provided from financing activities	(21,733)	(74,910)
	-	
Net increase in cash and equivalentes before foreign exchange adjustments coming from International operations and inflationary effects.	29,681	(231,900)
	-	
Foreign exchange and inflationary effects from International operations	(2,093)	(4,816)
	-	
Net increase (decrease) in cash	27,588	(236,716)
	-	
Cash and equivalents beginning of period	1,050,828	1,315,132
	-	
Cash and equivalente end period balance.	1,078,416	1,078,416
	-	
less- Employees shares fund	8,142	8,142
less- Share repurchasing fund	10,894	10,894
	-	
Cash and equivalente end period balance for operation	1,059,380	1,059,380